Navigation Links
Nanoparticles for delivery of prostate cancer treatment

Alan Garen, professor of molecular biophysics and biochemistry at Yale has received a $100,000 award from the Prostate Cancer Foundation to expand research on the delivery of a targeted therapy for prostate cancer using nanoparticles.

Garen and his collaborator Zhiwei Hu have developed a way to directly target and destroy the blood vessels of solid tumors, thus destroying the tumors while leaving normal tissue unharmed.

The technology uses a synthetic gene encoding an antibody-like molecule that activates an immune response to destroy the tumor blood vessels and associated tumors.

Garen previously received grants from the National Cancer Institute and Breast Cancer Alliance for Icon projects. The grant from the Prostate Cancer Foundation will extend his research to prostate cancer, which is the most common non-skin cancer in the United States.

Prostate cancer strikes one in six men. In 2007 alone, more than 200,000 men will be diagnosed with prostate cancer and more than 25,000 men will die of the disease. As the Baby Boomer generation begins to turn 60, increasing numbers of men are in the highest-risk sector for the disease. Over the next decade, the number of new cases is expected to increase to more than 300,000 annually.

The molecule that Garen and Hu constructed, called an Icon, recognizes the receptor tissue factor (TF) found on cells lining the inner surface of blood vessels in tumors but not in normal tissues. The Icon binds to TF more strongly and specifically than a natural antibody. Because the Icon acts through the blood, it can reach metastatic tumors throughout the body, which is critical for effective cancer therapy.

With the Prostate Foundation funding Garen will test the efficacy and safety of using targeted liposomal nanoparticle vectors ?lipid-covered, gene deli very packets ?to deliver the therapy in animal models of human metastatic prostate cancer.

"While we can directly inject the purified Icon molecule into the bloodstream, this procedure is less effective than having the Icon synthesized in vivo" said Garen. "We prefer to deliver the Icon gene to tumor cells, so that they cause their own destruction."

The Yale scientists previously used a virus to deliver the Icon gene, a system that was effective and safe in animal models and is being prepared for a clinical trial.

"The advantage of nanoparticle vectors is that they do not reproduce, are not immunogenic, and are easier to produce than adenoviral vectors," said Garen. The nanoparticles will have a tag on their outside that binds to the tumor blood vessels. After binding, they are taken up by the cells and unload the gene that codes for the Icon, allowing the cells to produce and secrete the Icon.

"The key is to have an efficient and safe way to deliver a specific and effective therapeutic agent," said Garen. "Having the nanoparticle targeted specifically to tumor blood vessels, and the Icon derived entirely from human components, should enhance the safety and efficacy of the procedure."


'"/>

Source:Yale University


Related biology news :

1. DNA Molecules Used To Assemble Nanoparticles
2. Imaging Lymph Nodes with Nanoparticles
3. Probing The Promise And Perils Of Nanoparticles
4. Nanoparticles offer new hope for detection and treatment
5. Nanoparticles carry cancer-killing drugs into tumor cells
6. Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer
7. Nanoparticles can track cells deep within living organisms
8. Cancer tip -- Nanoparticles can damage DNA, increase cancer risk
9. New methods of gene delivery using lasers
10. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
11. Self-assembled DNA buckyballs for drug delivery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... January 19, 2017 , ... ... for pharmaceutical research and development (R&D), today announced the launch of ... and interpretation for the rapidly evolving field of precision medicine. , ...
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
(Date:1/19/2017)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ), ... a live webcast of its Annual Meeting of Shareholders on Tuesday, ... webcast can be accessed from the BD corporate website at ... 2017. ... BD BD is a global medical technology company that is ...
Breaking Biology Technology: